Preventative Care & Screening
for Men
Speak to your physician about if it is right for you.
Digital rectal exam (DRE) or Prostate specific antigen (PSA)
CTFPHC recommends against screening with PSA
- Urological associations suggest discussing risks and benefits of PSA screening with patients >50yo (or >40yo if family history or African American) with >15y life expectancy
- Meta-analysis found no statistically significant differences in prostate cancer-specific mortality or all-cause mortality
- Only two studies have found a statistically significant decrease in prostate cancer-specific mortality (NNS 791 in ERSPC 2014, and NNS 139 in Goteborg 2014)
- Over-diagnosis up to 67% for PSA screening (leads to unnecessary biopsy and treatment of clinically insignificant prostate cancer)
- Harms of screening include infection, hospitalization, death (0.17% of biopsies following a positive PSA screening test)
Starting at age 65-80 – with one time screening ultrasound for abdominal aortic aneurysm.
